Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 95

1.

Advancing nonclinical innovation and safety in pharmaceutical testing.

Baker EJ, Beck NA, Berg EL, Clayton-Jeter HD, Chandrasekera PC, Curley JL, Donzanti BA, Ewart LC, Gunther JM, Kenna JG, LeCluyse EL, Liebman MN, Pugh CL, Watkins PB, Sullivan KM.

Drug Discov Today. 2018 Nov 20. pii: S1359-6446(18)30264-2. doi: 10.1016/j.drudis.2018.11.011. [Epub ahead of print] Review.

2.

Better science for safer medicines: the human imperative.

Archibald K, Tsaioun K, Kenna JG, Pound P.

J R Soc Med. 2018 Nov 15:141076818812783. doi: 10.1177/0141076818812783. [Epub ahead of print] No abstract available.

PMID:
30439294
3.

Can Bile Salt Export Pump Inhibition Testing in Drug Discovery and Development Reduce Liver Injury Risk? An International Transporter Consortium Perspective.

Kenna JG, Taskar KS, Battista C, Bourdet DL, Brouwer KLR, Brouwer KR, Dai D, Funk C, Hafey MJ, Lai Y, Maher J, Pak YA, Pedersen JM, Polli JW, Rodrigues AD, Watkins PB, Yang K, Yucha RW; International Transporter Consortium.

Clin Pharmacol Ther. 2018 Nov;104(5):916-932. doi: 10.1002/cpt.1222. Review.

4.

Do In Vitro Assays Predict Drug Candidate Idiosyncratic Drug-Induced Liver Injury Risk?

Kenna JG, Uetrecht J.

Drug Metab Dispos. 2018 Nov;46(11):1658-1669. doi: 10.1124/dmd.118.082719. Epub 2018 Jul 18.

PMID:
30021844
5.

Human biology-based drug safety evaluation: scientific rationale, current status and future challenges.

Kenna JG.

Expert Opin Drug Metab Toxicol. 2017 May;13(5):567-574. doi: 10.1080/17425255.2017.1290082. Epub 2017 Feb 14. Review.

PMID:
28150517
6.

Improved hepatic physiology in hepatic cytochrome P450 reductase null (HRN™) mice dosed orally with fenclozic acid.

Akingbasote JA, Foster AJ, Jones HB, David R, Gooderham NJ, Wilson ID, Kenna JG.

Toxicol Res (Camb). 2016 Nov 9;6(1):81-88. doi: 10.1039/c6tx00376a. eCollection 2017 Jan 1.

7.

Key Challenges and Opportunities Associated with the Use of In Vitro Models to Detect Human DILI: Integrated Risk Assessment and Mitigation Plans.

Atienzar FA, Blomme EA, Chen M, Hewitt P, Kenna JG, Labbe G, Moulin F, Pognan F, Roth AB, Suter-Dick L, Ukairo O, Weaver RJ, Will Y, Dambach DM.

Biomed Res Int. 2016;2016:9737920. Epub 2016 Sep 5. Review.

8.

Systems toxicology: modelling biomarkers of glutathione homeostasis and paracetamol metabolism.

Stahl SH, Yates JW, Nicholls AW, Kenna JG, Coen M, Ortega F, Nicholson JK, Wilson ID.

Drug Discov Today Technol. 2015 Aug;15:9-14. doi: 10.1016/j.ddtec.2015.06.003. Epub 2015 Jul 16. Review.

9.

Quantification of Drug-Induced Inhibition of Canalicular Cholyl-l-Lysyl-Fluorescein Excretion From Hepatocytes by High Content Cell Imaging.

Barber JA, Stahl SH, Summers C, Barrett G, Park BK, Foster JR, Kenna JG.

Toxicol Sci. 2015 Nov;148(1):48-59. doi: 10.1093/toxsci/kfv159. Epub 2015 Jul 27.

PMID:
26220638
10.

Hepatic effects of repeated oral administration of diclofenac to hepatic cytochrome P450 reductase null (HRN™) and wild-type mice.

Akingbasote JA, Foster AJ, Wilson I, Sarda S, Jones HB, Kenna JG.

Arch Toxicol. 2016 Apr;90(4):853-62. doi: 10.1007/s00204-015-1505-x. Epub 2015 Mar 28.

PMID:
25820915
11.

Multiple compound-related adverse properties contribute to liver injury caused by endothelin receptor antagonists.

Kenna JG, Stahl SH, Eakins JA, Foster AJ, Andersson LC, Bergare J, Billger M, Elebring M, Elmore CS, Thompson RA.

J Pharmacol Exp Ther. 2015 Feb;352(2):281-90. doi: 10.1124/jpet.114.220491. Epub 2014 Dec 2.

12.

Current Concepts in Drug-Induced Bile Salt Export Pump (BSEP) Interference.

Kenna JG.

Curr Protoc Toxicol. 2014 Aug 7;61:23.7.1-15. doi: 10.1002/0471140856.tx2307s61.

PMID:
25104267
13.

Mass spectrometric characterization of circulating covalent protein adducts derived from a drug acyl glucuronide metabolite: multiple albumin adductions in diclofenac patients.

Hammond TG, Meng X, Jenkins RE, Maggs JL, Castelazo AS, Regan SL, Bennett SN, Earnshaw CJ, Aithal GP, Pande I, Kenna JG, Stachulski AV, Park BK, Williams DP.

J Pharmacol Exp Ther. 2014 Aug;350(2):387-402. doi: 10.1124/jpet.114.215079. Epub 2014 Jun 5.

14.

Evaluation of the use of imaging parameters for the detection of compound-induced hepatotoxicity in 384-well cultures of HepG2 cells and cryopreserved primary human hepatocytes.

Garside H, Marcoe KF, Chesnut-Speelman J, Foster AJ, Muthas D, Kenna JG, Warrior U, Bowes J, Baumgartner J.

Toxicol In Vitro. 2014 Mar;28(2):171-81. doi: 10.1016/j.tiv.2013.10.015. Epub 2013 Nov 1.

15.

A correlation between the in vitro drug toxicity of drugs to cell lines that express human P450s and their propensity to cause liver injury in humans.

Gustafsson F, Foster AJ, Sarda S, Bridgland-Taylor MH, Kenna JG.

Toxicol Sci. 2014 Jan;137(1):189-211. doi: 10.1093/toxsci/kft223. Epub 2013 Oct 1.

PMID:
24085192
16.

Glutathione metabolism modeling: a mechanism for liver drug-robustness and a new biomarker strategy.

Geenen S, du Preez FB, Snoep JL, Foster AJ, Sarda S, Kenna JG, Wilson ID, Westerhoff HV.

Biochim Biophys Acta. 2013 Oct;1830(10):4943-59. doi: 10.1016/j.bbagen.2013.04.014. Epub 2013 Apr 30.

PMID:
23643929
17.
18.

In vitro exploration of potential mechanisms of toxicity of the human hepatotoxic drug fenclozic acid.

Rodrigues AV, Rollison HE, Martin S, Sarda S, Schulz-Utermoehl T, Stahl S, Gustafsson F, Eakins J, Kenna JG, Wilson ID.

Arch Toxicol. 2013 Aug;87(8):1569-79. doi: 10.1007/s00204-013-1056-y. Epub 2013 Apr 23.

PMID:
23609606
19.

Assessment of gadoxetate DCE-MRI as a biomarker of hepatobiliary transporter inhibition.

Ulloa JL, Stahl S, Yates J, Woodhouse N, Kenna JG, Jones HB, Waterton JC, Hockings PD.

NMR Biomed. 2013 Oct;26(10):1258-70. doi: 10.1002/nbm.2946. Epub 2013 Apr 7.

20.

Bioactivation of the cannabinoid receptor antagonist rimonabant to a cytotoxic iminium ion metabolite.

Foster AJ, Prime LH, Gustafsson F, Temesi DG, Isin EM, Midlöv J, Castagnoli N Jr, Kenna JG.

Chem Res Toxicol. 2013 Jan 18;26(1):124-35. doi: 10.1021/tx300418w. Epub 2012 Dec 12.

PMID:
23234359
21.

The gasotransmitter hydrogen sulfide induces nrf2-target genes by inactivating the keap1 ubiquitin ligase substrate adaptor through formation of a disulfide bond between cys-226 and cys-613.

Hourihan JM, Kenna JG, Hayes JD.

Antioxid Redox Signal. 2013 Aug 10;19(5):465-81. doi: 10.1089/ars.2012.4944. Epub 2013 Jan 16.

PMID:
23145493
22.

A new twist to an old tale: novel insights into the differential toxicities of acetaminophen and its regioisomer N-acetyl-meta-aminophenol (AMAP).

Kenna JG.

Arch Toxicol. 2013 Jan;87(1):15-8. doi: 10.1007/s00204-012-0945-9. Epub 2012 Sep 23. No abstract available.

PMID:
23001139
23.

Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.

Warner DJ, Chen H, Cantin LD, Kenna JG, Stahl S, Walker CL, Noeske T.

Drug Metab Dispos. 2012 Dec;40(12):2332-41. doi: 10.1124/dmd.112.047068. Epub 2012 Sep 7.

24.

Characterization of THLE-cytochrome P450 (P450) cell lines: gene expression background and relationship to P450-enzyme activity.

Soltanpour Y, Hilgendorf C, Ahlström MM, Foster AJ, Kenna JG, Petersen A, Ungell AL.

Drug Metab Dispos. 2012 Nov;40(11):2054-8. doi: 10.1124/dmd.112.045815. Epub 2012 Jul 30.

25.

In vitro approach to assess the potential for risk of idiosyncratic adverse reactions caused by candidate drugs.

Thompson RA, Isin EM, Li Y, Weidolf L, Page K, Wilson I, Swallow S, Middleton B, Stahl S, Foster AJ, Dolgos H, Weaver R, Kenna JG.

Chem Res Toxicol. 2012 Aug 20;25(8):1616-32. doi: 10.1021/tx300091x. Epub 2012 May 31.

PMID:
22646477
26.

Systems biology tools for toxicology.

Geenen S, Taylor PN, Snoep JL, Wilson ID, Kenna JG, Westerhoff HV.

Arch Toxicol. 2012 Aug;86(8):1251-71. doi: 10.1007/s00204-012-0857-8. Epub 2012 May 9. Review.

PMID:
22569772
27.

The HepaRG cell line: a unique in vitro tool for understanding drug metabolism and toxicology in human.

Andersson TB, Kanebratt KP, Kenna JG.

Expert Opin Drug Metab Toxicol. 2012 Jul;8(7):909-20. doi: 10.1517/17425255.2012.685159. Epub 2012 May 8. Review.

PMID:
22568886
28.

Evaluation of the pharmacokinetics, biotransformation and hepatic transporter effects of troglitazone in mice with humanized livers.

Schulz-Utermoehl T, Sarda S, Foster JR, Jacobsen M, Kenna JG, Morikawa Y, Salmu J, Gross G, Wilson ID.

Xenobiotica. 2012 Jun;42(6):503-17. doi: 10.3109/00498254.2011.640716. Epub 2011 Dec 27.

PMID:
22201515
29.

In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans.

Dawson S, Stahl S, Paul N, Barber J, Kenna JG.

Drug Metab Dispos. 2012 Jan;40(1):130-8. doi: 10.1124/dmd.111.040758. Epub 2011 Sep 30.

30.

A mathematical modelling approach to assessing the reliability of biomarkers of glutathione metabolism.

Geenen S, du Preez FB, Reed M, Nijhout HF, Kenna JG, Wilson ID, Westerhoff HV, Snoep JL.

Eur J Pharm Sci. 2012 Jul 16;46(4):233-43. doi: 10.1016/j.ejps.2011.08.017. Epub 2011 Aug 24.

PMID:
21888969
31.

HPLC-MS/MS methods for the quantitative analysis of 5-oxoproline (pyroglutamate) in rat plasma and hepatic cell line culture medium.

Geenen S, Guallar-Hoyas C, Michopoulos F, Kenna JG, Kolaja KL, Westerhoff HV, Thomas P, Wilson ID.

J Pharm Biomed Anal. 2011 Nov 1;56(3):655-63. doi: 10.1016/j.jpba.2011.06.001. Epub 2011 Jun 13.

PMID:
21752568
32.

Managing the challenge of chemically reactive metabolites in drug development.

Park BK, Boobis A, Clarke S, Goldring CE, Jones D, Kenna JG, Lambert C, Laverty HG, Naisbitt DJ, Nelson S, Nicoll-Griffith DA, Obach RS, Routledge P, Smith DA, Tweedie DJ, Vermeulen N, Williams DP, Wilson ID, Baillie TA.

Nat Rev Drug Discov. 2011 Apr;10(4):292-306. doi: 10.1038/nrd3408. Review.

PMID:
21455238
33.

HPLC-MS/MS methods for the quantitative analysis of ophthalmic acid in rodent plasma and hepatic cell line culture medium.

Geenen S, Michopoulos F, Kenna JG, Kolaja KL, Westerhoff HV, Wilson I.

J Pharm Biomed Anal. 2011 Apr 5;54(5):1128-35. doi: 10.1016/j.jpba.2010.11.038. Epub 2010 Dec 2.

PMID:
21176868
34.

Risk assessment and mitigation strategies for reactive metabolites in drug discovery and development.

Thompson RA, Isin EM, Li Y, Weaver R, Weidolf L, Wilson I, Claesson A, Page K, Dolgos H, Kenna JG.

Chem Biol Interact. 2011 Jun 30;192(1-2):65-71. doi: 10.1016/j.cbi.2010.11.002. Epub 2010 Nov 11.

PMID:
21074519
35.

Cell based approaches for evaluation of drug-induced liver injury.

Greer ML, Barber J, Eakins J, Kenna JG.

Toxicology. 2010 Feb 9;268(3):125-31. doi: 10.1016/j.tox.2009.08.007. Epub 2009 Aug 13. Review.

PMID:
19683031
36.

Functional and toxicological consequences of metabolic bioactivation of methapyrilene via thiophene S-oxidation: Induction of cell defence, apoptosis and hepatic necrosis.

Mercer AE, Regan SL, Hirst CM, Graham EE, Antoine DJ, Benson CA, Williams DP, Foster J, Kenna JG, Park BK.

Toxicol Appl Pharmacol. 2009 Sep 15;239(3):297-305. doi: 10.1016/j.taap.2009.05.027. Epub 2009 Jun 10.

PMID:
19523481
37.

Identification of the thiophene ring of methapyrilene as a novel bioactivation-dependent hepatic toxicophore.

Graham EE, Walsh RJ, Hirst CM, Maggs JL, Martin S, Wild MJ, Wilson ID, Harding JR, Kenna JG, Peter RM, Williams DP, Park BK.

J Pharmacol Exp Ther. 2008 Aug;326(2):657-71. doi: 10.1124/jpet.107.135483. Epub 2008 May 1.

38.

Primary hepatocytes: current understanding of the regulation of metabolic enzymes and transporter proteins, and pharmaceutical practice for the use of hepatocytes in metabolism, enzyme induction, transporter, clearance, and hepatotoxicity studies.

Hewitt NJ, Lechón MJ, Houston JB, Hallifax D, Brown HS, Maurel P, Kenna JG, Gustavsson L, Lohmann C, Skonberg C, Guillouzo A, Tuschl G, Li AP, LeCluyse E, Groothuis GM, Hengstler JG.

Drug Metab Rev. 2007;39(1):159-234. Review.

PMID:
17364884
39.

Hepatic adducts, circulating antibodies, and cytokine polymorphisms in patients with diclofenac hepatotoxicity.

Aithal GP, Ramsay L, Daly AK, Sonchit N, Leathart JB, Alexander G, Kenna JG, Caldwell J, Day CP.

Hepatology. 2004 May;39(5):1430-40.

PMID:
15122773
40.

Cellular models for ADMET predictions and evaluation of drug-drug interactions.

Riley RJ, Kenna JG.

Curr Opin Drug Discov Devel. 2004 Jan;7(1):86-99. Review.

PMID:
14982152
41.

Immunogenic properties of rapidly digested food proteins following gavage exposure of mice: a comparison of ovalbumin with a potato acid phosphatase preparation.

Dearman RJ, Caddick H, Stone S, Kenna JG, Basketter DA, Kimber I.

Food Chem Toxicol. 2002 May;40(5):625-33.

PMID:
11955668
42.

Predictive methods for food allergenicity: perspectives and current status.

Kimber I, Atherton K, Kenna JG, Dearman RJ.

Toxicology. 2000 Jun 8;147(2):147-50. No abstract available.

PMID:
10939975
43.

Interindividual variability in P450-dependent generation of neoantigens in halothane hepatitis.

Eliasson E, Gardner I, Hume-Smith H, de Waziers I, Beaune P, Kenna JG.

Chem Biol Interact. 1998 Nov 6;116(1-2):123-41.

PMID:
9877205
44.

Gallstones and isoflurane hepatitis.

Meldrum DJ, Griffiths R, Kenna JG.

Anaesthesia. 1998 Sep;53(9):905-9.

45.

Immunochemical identification of hepatic protein adducts derived from estragole.

Wakazono H, Gardner I, Eliasson E, Coughtrie MW, Kenna JG, Caldwell J.

Chem Res Toxicol. 1998 Aug;11(8):863-72.

PMID:
9705747
46.

Cytochrome P450 mediated bioactivation of methyleugenol to 1'-hydroxymethyleugenol in Fischer 344 rat and human liver microsomes.

Gardner I, Wakazono H, Bergin P, de Waziers I, Beaune P, Kenna JG, Caldwell J.

Carcinogenesis. 1997 Sep;18(9):1775-83.

PMID:
9328175
48.

Immunoallergic drug-induced hepatitis: lessons from halothane.

Kenna JG.

J Hepatol. 1997;26 Suppl 1:5-12. Review. No abstract available.

PMID:
9138123
49.

Patients must be a virtue.

Kenna JG.

Hum Exp Toxicol. 1996 Dec;15(12):981-3. No abstract available.

PMID:
8981103
50.

Cytochrome P450 2E1 is a cell surface autoantigen in halothane hepatitis.

Eliasson E, Kenna JG.

Mol Pharmacol. 1996 Sep;50(3):573-82.

PMID:
8794896

Supplemental Content

Loading ...
Support Center